CL2018000351A1 - Compuestos antivirales de fosfodiamida de éster de beta-aminoácido - Google Patents

Compuestos antivirales de fosfodiamida de éster de beta-aminoácido

Info

Publication number
CL2018000351A1
CL2018000351A1 CL2018000351A CL2018000351A CL2018000351A1 CL 2018000351 A1 CL2018000351 A1 CL 2018000351A1 CL 2018000351 A CL2018000351 A CL 2018000351A CL 2018000351 A CL2018000351 A CL 2018000351A CL 2018000351 A1 CL2018000351 A1 CL 2018000351A1
Authority
CL
Chile
Prior art keywords
ester
beta
amino acid
phosphodiamide
antiviral compounds
Prior art date
Application number
CL2018000351A
Other languages
English (en)
Inventor
Petr Vachal
Izzat Raheem
Zhiqiang Guo
Timothy John Hartingh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56852398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018000351(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2018000351A1 publication Critical patent/CL2018000351A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LOS COMPUESTOS DE FÓRMULA I, Y SUS SALES FARMACÉUTICAMENTE ACEPTABLES SON ÚTILES PARA LA INHIBICIÓN DE LA TRANSCRIPTASA INVERSA DEL VIH. LOS COMPUESTOS TAMBIÉN PUEDEN SER ÚTILES PARA LA PROFILAXIS O EL TRATAMIENTO DE LA INFECCIÓN POR VIH, Y EN LA PROFILAXIS, EL RETRASO DE LA APARICIÓN O LA PROGRESIÓN Y EL TRATAMIENTO DEL SIDA. LOS COMPUESTOS Y SUS SALES SE PUEDEN EMPLEAR COMO INGREDIENTES EN COMPOSICIONES FARMACÉUTICAS, OPCIONALMENTE, EN COMBINACIÓN CON OTROS AGENTES ANTIVIRALES, INMUNOMODULADORES, ANTIBIÓTICOS O VACUNAS.</p>
CL2018000351A 2015-08-10 2018-02-07 Compuestos antivirales de fosfodiamida de éster de beta-aminoácido CL2018000351A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562203265P 2015-08-10 2015-08-10

Publications (1)

Publication Number Publication Date
CL2018000351A1 true CL2018000351A1 (es) 2018-07-06

Family

ID=56852398

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000351A CL2018000351A1 (es) 2015-08-10 2018-02-07 Compuestos antivirales de fosfodiamida de éster de beta-aminoácido

Country Status (26)

Country Link
US (2) US9822138B2 (es)
EP (1) EP3334743B1 (es)
JP (2) JP6563585B2 (es)
KR (1) KR102163611B1 (es)
CN (1) CN107849071B (es)
AR (1) AR105643A1 (es)
AU (1) AU2016305941B2 (es)
CA (1) CA2994720C (es)
CL (1) CL2018000351A1 (es)
CO (1) CO2018001296A2 (es)
CR (1) CR20180092A (es)
EA (1) EA035028B1 (es)
EC (1) ECSP18018823A (es)
HK (1) HK1249107A1 (es)
IL (1) IL257156A (es)
MA (1) MA42615A (es)
MX (1) MX2018001729A (es)
MY (1) MY192607A (es)
NI (1) NI201800023A (es)
PE (1) PE20181016A1 (es)
PH (1) PH12018500292A1 (es)
SV (1) SV2018005629A (es)
TN (1) TN2018000048A1 (es)
TW (1) TWI639598B (es)
WO (1) WO2017027434A1 (es)
ZA (1) ZA201800514B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3285582B1 (en) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
JP2017182110A (ja) * 2016-03-28 2017-10-05 セイコーエプソン株式会社 表示システム、表示装置、情報処理装置及び情報処理方法
EP3503895B1 (en) 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
MX2019007585A (es) 2016-12-22 2019-09-09 Merck Sharp & Dohme Profarmacos de ester alifatico antiviricos de tenofovir.
CA3046029A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
EP3823629A4 (en) 2018-07-19 2022-05-04 Merck Sharp & Dohme Corp. PHOSPHINAMIDE PRODRUGS OF TENOFOVIR
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
AR115936A1 (es) * 2018-08-09 2021-03-17 Glaxosmithkline Ip No 2 Ltd Compuestos útiles en terapia del vih
CN108623632A (zh) * 2018-08-17 2018-10-09 上海麦步医药科技有限公司 一种替诺福韦艾拉酚胺的制备方法
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US20220119426A1 (en) 2020-08-07 2022-04-21 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP1240174A2 (en) * 1999-12-22 2002-09-18 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
HRP20160074B1 (hr) 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
DK2038290T3 (da) 2006-07-07 2013-12-02 Gilead Sciences Inc Modulatorer af toll-lignende receptor 7
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
UA115311C2 (uk) 2011-08-16 2017-10-25 Гіліад Сайєнсіз, Інк. Геміфумарат тенофовіру алафенаміду
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds

Also Published As

Publication number Publication date
EA201890425A1 (ru) 2018-07-31
US20170044192A1 (en) 2017-02-16
CN107849071B (zh) 2021-03-09
CO2018001296A2 (es) 2018-07-19
MY192607A (en) 2022-08-29
PE20181016A1 (es) 2018-06-26
HK1249107A1 (zh) 2018-10-26
IL257156A (en) 2018-03-29
CN107849071A (zh) 2018-03-27
TWI639598B (zh) 2018-11-01
WO2017027434A1 (en) 2017-02-16
EP3334743B1 (en) 2023-11-29
TW201712014A (zh) 2017-04-01
JP2018531216A (ja) 2018-10-25
AU2016305941B2 (en) 2018-11-15
EP3334743A1 (en) 2018-06-20
MX2018001729A (es) 2018-05-17
KR20180030226A (ko) 2018-03-21
SV2018005629A (es) 2018-06-12
US9822138B2 (en) 2017-11-21
TN2018000048A1 (en) 2019-07-08
NI201800023A (es) 2018-06-12
EA035028B1 (ru) 2020-04-20
CA2994720C (en) 2020-11-03
US20180065999A1 (en) 2018-03-08
CR20180092A (es) 2018-04-02
ZA201800514B (en) 2018-12-19
JP2019194200A (ja) 2019-11-07
AR105643A1 (es) 2017-10-25
JP6563585B2 (ja) 2019-08-21
AU2016305941A1 (en) 2018-02-15
MA42615A (fr) 2018-06-20
PH12018500292A1 (en) 2018-08-20
ECSP18018823A (es) 2018-07-31
KR102163611B1 (ko) 2020-10-08
CA2994720A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
CL2018000351A1 (es) Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
NI201500048A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
DOP2016000265A (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
SV2009003294A (es) Inhibidores de transcriptasa inversa no nucleosidicos
UY36212A (es) Moduladores de receptores tipo toll para el tratamiento del vih
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
CO6382127A2 (es) Inhibidores de la integrasa del vih
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
AR099428A1 (es) Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles